StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Oppenheimer on Gilead Sciences (GILD): 'Story Near-Term Remains Squarely HIV Focused'
April 8, 2026 6:01 AM
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $165.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst comments "Gilead's ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
